Filing Analysis
HealthLynked Corp. announced a significant restructuring of its executive leadership, including the appointment of an interim CFO, the transition of the current CFO to a non-executive role, and the elimination of the COO position.
🚩 Red Flags
- Multiple officer departures/transitions in a single filing (CFO and COO).
- Elimination of the COO position suggests cost-cutting or organizational instability.
- Interim CFO appointment often indicates a vacancy in permanent leadership or internal transition issues.
📋 Key Facts
- George O’Leary appointed as part-time Interim CFO effective July 13, 2026.
- Interim CFO compensation includes $15,000 per month for three days of work per week.
- Mr. O'Leary granted 35,000 stock options with an exercise price of $3.50, vesting upon Nasdaq listing approval.
- Jeremy Daniel transitioned from CFO to a corporate accounting role effective July 13, 2026; no disagreement reported.
- Duncan McGillivray's COO position will be eliminated on July 24, 2026; he will move to a Senior Strategic Advisor role via an independent consulting agreement.
HealthLynked Corp. announced several leadership changes, including the appointment of Duncan McGillivray as Chief Operating Officer and two new directors, Jason Bishara and Chris G. Pulos, to expand the Board.
🚩 Red Flags
- Compensation for the new COO is explicitly tied to a 'successful Uplisting' to the Nasdaq Capital Market, indicating the company's current status is likely on a lower tier (e.g., OTC) and focused on an exit/uplisting strategy.
📋 Key Facts
- Duncan McGillivray appointed as COO effective December 8, 2025; base salary $120,000 with an increase to $150,000 upon Nasdaq uplisting.
- McGillivray to receive up to 180,000 RSUs (90,000 vesting over three years, 90,000 vesting upon Nasdaq uplisting).
- Jason Bishara appointed to Board effective December 1, 2025; annual compensation of $20,000 in Company common stock.
- Chris G. Pulos appointed to Board effective December 1, 2025; annual compensation of $20,000 in Company common stock.
- The Board size increased from six members to eight members.
HealthLynked Corp. has implemented a 1-for-100 reverse stock split effective September 4, 2025. The split significantly reduces the total number of outstanding shares from approximately 284.7 million to roughly 2.85 million.
🚩 Red Flags
- Reverse stock split (often used to combat delisting or signal financial distress).
- Significant reduction in share count/liquidity profile.
📋 Key Facts
- Reverse stock split ratio: 1-for-100.
- Market Effective Date: September 4, 2025.
- Ticker symbol change: Will trade as 'HLYKD' for 20 trading days on the OTCQB.
- Outstanding shares reduced from 284,778,332 to approximately 2,847,784.
- Fractional shares are being rounded up to the nearest whole share; no cash in lieu of fractional shares will be paid.
- CUSIP number changed to 42228P 300.
HealthLynked Corp. issued a $420,000 convertible promissory note and entered into a notes extension agreement with the Mary S. Dent Gifting Trust, an entity controlled by the Company's CEO and Chairman, Dr. Michael Dent. The transactions involve significant debt extensions and the issuance of warrants to the CEO-controlled trust.
🚩 Red Flags
- Related-party transaction: The debt and warrants were issued to an entity controlled by the CEO/Chairman.
- Significant dilution risk: Issuance of over 1.3 million warrants at a very low strike price ($0.0375) and conversion of existing notes.
- Debt restructuring with insider: Extending $1.2M in debt and issuing warrants to an insider is a classic red flag for micro-cap companies.
- High interest rates: 12%–18% on the new note and 15% on extended notes indicate high cost of capital/distress.
📋 Key Facts
- Issued $420,000 convertible promissory note to Mary S. Dent Gifting Trust on March 20, 2025.
- The Purchaser (Mary S. Dent Gifting Trust) is controlled by CEO and Chairman Dr. Michael Dent.
- Note matures September 20, 2025; carries 12% interest, increasing to 18% upon default.
- Conversion price set at $0.0375 per share.
- Extended twelve existing notes totaling $1,216,500 to a new maturity date of September 20, 2025.
- In exchange for the extension, the Company issued a 10-year warrant for 1,353,356 shares at $0.0375 per share.
- Interest rate on extended notes increased from 12% to 15%.
HealthLynked Corp. issued a shareholder letter and a press release on February 4, 2025, via an Item 8.01 'Other Events' filing. The specific contents of the letter are not detailed in the 8-K text but are provided as exhibits.
🚩 Red Flags
- Use of Item 8.01 often indicates significant corporate developments that do not fit standard categories, which can sometimes signal distress or major structural changes when combined with other filings.
📋 Key Facts
- Filing date: February 4, 2025
- The company issued a Shareholder Letter (Exhibit 99.1) and a Press Release (Exhibit 99.2).
- The filing was signed by CFO Jeremy Daniel.
HealthLynked Corp. announced a change in its executive leadership, effective January 15, 2025. The company appointed Jeremy Daniel as part-time Chief Financial Officer and announced the resignation of David Rosal.
🚩 Red Flags
- Transition to a part-time CFO may indicate cost-cutting measures or limited internal resources common in micro-cap companies.
📋 Key Facts
- Effective January 15, 2025, Jeremy Daniel was appointed as part-time CFO.
- Mr. Daniel will work two days per week with a base salary of $66,000 per year.
- David Rosal resigned as CFO; the company stated the resignation was not due to any disagreement with management or the Board.
- Jeremy Daniel is a CPA with previous CFO experience at Innoveren Scientific and Regenerative Medicine Solutions.
HealthLynked Corp. issued ten senior secured convertible promissory notes totaling $900,000 and a warrant to purchase 9,259,258 shares of common stock to the Mary S. Dent Gifting Trust. The transaction is a related-party deal as the Purchaser is controlled by the Company's CEO and Chairman, Dr. Michael Dent.
🚩 Red Flags
- Related-party transaction: The purchaser is controlled by the CEO and Chairman, Dr. Michael Dent.
- Highly dilutive financing: Issuance of over 9 million warrants at a very low conversion price ($0.0486).
- Senior secured debt: The notes are backed by a first priority lien on all company assets, placing the lender (CEO's trust) ahead of other creditors.
- High interest rate penalty: Interest jumps from 12% to 18% upon default.
📋 Key Facts
- Issued $900,000 in aggregate principal amount via ten senior secured convertible promissory notes on September 19, 2024.
- Net proceeds to the company were $855,000 after a 5% original issue discount.
- The Notes carry a 12% annual interest rate, increasing to 18% in the event of default.
- Notes are convertible at a price of $0.0486 per share; Warrant exercise price is also $0.0486 per share.
- Warrant allows for the purchase of 9,259,258 shares with a 10-year term.
- The Notes are secured by a first priority lien on all Company assets.
- Maturity dates for the notes range from January 2025 to March 2025.
HealthLynked Corp. announced the appointment of William Crupi as Chief Operating Officer, effective June 25, 2024. Mr. Crupi transitions from his role as Operations Manager to this executive position.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- William Crupi appointed as Chief Operating Officer (COO) effective June 25, 2024.
- Mr. Crupi previously served as the Company's Operations Manager since April 2023.
- Base salary for the new COO is set at $120,000 per year.
- Compensation includes a 10-year stock option to purchase 300,000 shares of common stock at an exercise price of $0.081.
- Stock options vest ratably over three years: June 25, 2025; June 25, 2026; and June 25, 2027.
HealthLynked Corp. issued a $1,000,000 senior secured convertible promissory note and warrants to the Mary S. Dent Gifting Trust, an entity controlled by the Company's CEO and Chairman, Dr. Michael Dent. The transaction is secured by a first priority lien on all company assets.
🚩 Red Flags
- Related-party transaction: The purchaser is controlled by the CEO/Chairman.
- Extremely high dilution risk: Issuance of 10,000,000 warrants at a very low price ($0.0497) and convertible note functionality.
- Asset encumbrance: A first priority lien has been placed on all company assets to secure the debt to the CEO's trust.
- Penalty interest rate: Interest jumps from 12% to 18% in the event of default.
📋 Key Facts
- Issued $1,000,000 senior secured convertible promissory note to Mary S. Dent Gifting Trust (controlled by CEO/Chairman Dr. Michael Dent).
- Net proceeds of $950,000 received due to a 5% original issue discount.
- Note carries a 12% annual interest rate, increasing to 18% upon an Event of Default.
- Warrant issued for 10,000,000 shares of common stock with an exercise price of $0.0497 and a 10-year term.
- Note matures on June 3, 2025, and is subject to mandatory conversion upon a Qualified Equity Financing or at maturity.
- The Note is secured by a first priority lien on all assets of the Company.
HealthLynked Corp. announced the appointment of David Rosal as Chief Financial Officer, effective March 11, 2024. Mr. Rosal brings extensive corporate experience from Teradata and McDonald’s Corporation.
📋 Key Facts
- David Rosal appointed as CFO effective March 11, 2024.
- Base salary set at $150,000 per year.
- Eligible for the Company's 2021 Equity Incentive Plan (EIP).
- Mr. Rosal previously held senior roles at Teradata and McDonald’s Corporation.
HealthLynked Corp. announced the resignation of George O'Leary from his position as Chief Financial Officer, effective April 4, 2024. The resignation is not due to any disagreement with the company or its board.
🚩 Red Flags
- Planned departure of a key financial officer (CFO) can sometimes precede internal restructuring or reporting changes, though not indicated here.
📋 Key Facts
- George O'Leary resigned as CFO on January 5, 2024.
- The resignation becomes effective on April 4, 2024.
- Mr. O'Leary will remain on the Company's Board of Directors.
- The company explicitly states there was no disagreement regarding the resignation.